Hims & Hers Expands Weight-Loss Offerings with New Medications

The telehealth company adds Eli Lilly's Zepbound, Mounjaro, and generic liraglutide to its platform but faces investor skepticism over pricing and partnerships.

Hims & Hers has introduced Eli Lilly's Zepbound and Mounjaro, as well as generic liraglutide, to its telehealth weight-loss platform.
Zepbound and Mounjaro are priced at $1,899 per month, while the generic liraglutide is offered at $299 per month, targeting more cost-sensitive customers.
Eli Lilly clarified it has no partnership with Hims & Hers, countering initial market confusion following the announcement.
Investor enthusiasm waned after the announcement, with concerns over the high cost of branded drugs and the revenue potential of the offerings.
The company is focusing on expanding its weight-loss program with personalized features and continues lobbying for access to compounded medications despite FDA restrictions.

Quartz

Investor's Business Daily